PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28685525-7 2017 IL-37 is a family member cytokine which binds IL-18 receptor alpha chain and inhibits inflammatory mediators including TNF, IL-1, IL-6, IL-33 and nitric oxide (NO). Nitric Oxide 146-158 interleukin 1 alpha Homo sapiens 46-50 31374866-8 2019 CONCLUSIONS: These results suggest that treatment with EEP in chondrocytes that were stimulated with IL-1beta has beneficial effects, such as a decrease in the expression of proteins associated with autophagy, MMP13, and production of nitric oxide, and also increased collagen II. Nitric Oxide 235-247 interleukin 1 alpha Homo sapiens 101-109 16540955-9 2006 Ischemic preconditioning, mediated by nitric oxide, reduced IL-1 release and protected against lung damage. Nitric Oxide 38-50 interleukin 1 alpha Homo sapiens 60-64 23706710-8 2013 TNFA GA and IL5 CC and TNFA GA and IL1A CC were 2 epistatic predictors of exhaled nitrogen monoxide decrease during follow-up (P = .02 and P = .004, respectively). Nitric Oxide 82-99 interleukin 1 alpha Homo sapiens 35-39 22481441-10 2012 Chondrocytes treated with IL-1 exhibit a characteristic increase in the release of the inflammatory chemokines, nitric oxide and prostaglandin E2. Nitric Oxide 112-124 interleukin 1 alpha Homo sapiens 26-30 21787135-6 2011 Visfatin and IL-1 promoted the catabolic degradation of both cartilage and meniscus, as evidenced by increased metalloproteinase activity, nitric oxide production, and proteoglycan release. Nitric Oxide 139-151 interleukin 1 alpha Homo sapiens 13-17 17945515-2 2008 Nitric oxide (NO) can mediate a number of the catabolic effects of IL-1 in articular cartilage. Nitric Oxide 0-12 interleukin 1 alpha Homo sapiens 67-71 16478776-0 2006 Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. Nitric Oxide 121-133 interleukin 1 alpha Homo sapiens 68-77 24152854-0 2013 Thermal water of Vetriolo, Trentino, inhibits the negative effect of interleukin-1β on nitric oxide production and apoptosis in human osteoarthritic chondrocyte. Nitric Oxide 96-108 interleukin 1 alpha Homo sapiens 69-82 22101739-0 2012 Regulation of IL-1beta-induced cyclooxygenase-2 expression by interactions of Abeta peptide, apolipoprotein E and nitric oxide in human neuroglioma. Nitric Oxide 114-126 interleukin 1 alpha Homo sapiens 14-22 21792375-3 2011 Additionally, microglial cells release IL-1alpha/beta, reactive oxygen species (ROS), such as superoxide (O(2) (-)) and reactive nitrogen species (RNS) like nitric oxide (NO). Nitric Oxide 157-169 interleukin 1 alpha Homo sapiens 39-48 19913562-0 2010 Nitric oxide and peroxynitrite induce gene expression of interleukin receptors increasing IL-21, IL-7, IL-1 and oncostatin M in cardiomyocytes. Nitric Oxide 0-12 interleukin 1 alpha Homo sapiens 103-107 18504291-9 2008 In vivo, we found that nitric oxide was a downstream molecule of IL-1 action and partially responsible for the exacerbation of neurodegeneration observed. Nitric Oxide 23-35 interleukin 1 alpha Homo sapiens 65-69 16540955-10 2006 Nitric oxide synthesis inhibition in the preconditioned group led to increased IL-1 levels and increased lung damage following ROLT, whereas the addition of IL-1 receptor antagonist protected against the injurious effects of nitric oxide inhibition. Nitric Oxide 0-12 interleukin 1 alpha Homo sapiens 79-83 16540955-11 2006 In addition, nitric oxide pretreatment gave similar results in terms of IL-1alpha and lung protection to those found in preconditioning. Nitric Oxide 13-25 interleukin 1 alpha Homo sapiens 72-81 16540955-14 2006 Similarly, nitric oxide synthesis inhibition in the preconditioned group, which increased IL-1alpha and lung damage, reduced systemic sTNFR2 and increased free TNF levels. Nitric Oxide 11-23 interleukin 1 alpha Homo sapiens 90-99 17027524-8 2006 Several in vitro studies have shown that IL-1 stimulates the production of mediators such as prostaglandin E(2), nitric oxide, cytokines, chemokines, and adhesion molecules that are involved in articular inflammation. Nitric Oxide 113-125 interleukin 1 alpha Homo sapiens 41-45 16354107-3 2006 IL-1, known to inhibit glucose-induced insulin secretion by stimulating inducible nitric oxide synthase expression and increased production of nitric oxide by beta-cells, also induces beta-cell death. Nitric Oxide 82-94 interleukin 1 alpha Homo sapiens 0-4 16354107-6 2006 In contrast, IL-1 stimulates the release of the immunological adjuvant high mobility group box 1 protein (HMGB1; a biochemical maker of necrosis) in a nitric oxide-dependent manner, while apoptosis inducers fail to stimulate HMGB1 release. Nitric Oxide 151-163 interleukin 1 alpha Homo sapiens 13-17 16261637-7 2006 Preconditioning inhibited IL-1 through nitric oxide (NO), thereby protecting against the injurious effects of IL-1. Nitric Oxide 39-51 interleukin 1 alpha Homo sapiens 26-30 16261637-7 2006 Preconditioning inhibited IL-1 through nitric oxide (NO), thereby protecting against the injurious effects of IL-1. Nitric Oxide 39-51 interleukin 1 alpha Homo sapiens 110-114 12846989-4 2003 Glial cells can release deleterious compounds such as proinflammatory cytokines (TNF-alpha, Il-1beta, IFN-gamma), which may act by stimulating nitric oxide production in glial cells, or which may exert a more direct deleterious effect on dopaminergic neurons by activating receptors that contain intracytoplasmic death domains involved in apoptosis. Nitric Oxide 143-155 interleukin 1 alpha Homo sapiens 92-100 15899045-8 2005 However, co-stimulation with leptin and IL-1 resulted in a net increase in nitric oxide concentration over IL-1 challenge that was eliminated by pretreatment with the NOS II specific inhibitor aminoguanidine. Nitric Oxide 75-87 interleukin 1 alpha Homo sapiens 40-44 15899045-9 2005 Pretreatment with tyrphostin AG490 and Tkip (a SOCS-1 mimetic peptide that inhibits JAK2) blocked nitric oxide production induced by leptin/IL-1. Nitric Oxide 98-110 interleukin 1 alpha Homo sapiens 140-144 16121032-2 2005 Generation of nitric oxide (NO) in response to IL-1 is implicated in these actions. Nitric Oxide 14-26 interleukin 1 alpha Homo sapiens 47-51 15209355-0 2004 N-palmitoylation of the radioprotective domain of interleukin-1 affords inhibition of LPS-induced nitric oxide generation. Nitric Oxide 98-110 interleukin 1 alpha Homo sapiens 50-63 14765973-8 2004 More precisely, IL-1 may be involved in several ovulation-associated events such as the synthesis of proteases, regulation of plasminogen activator activity, prostaglandin and nitric oxide production. Nitric Oxide 176-188 interleukin 1 alpha Homo sapiens 16-20 15899045-3 2005 For this purpose, nitric oxide production was evaluated using the Griess colorimetric reaction in culture medium of cells stimulated over 48 hours with leptin (800 nmol/l) and IL-1 (0.025 ng/ml), alone or combined. Nitric Oxide 18-30 interleukin 1 alpha Homo sapiens 176-180 15899045-6 2005 Our results indicate that stimulation of chondrocytes with IL-1 results in dose-dependent nitric oxide production. Nitric Oxide 90-102 interleukin 1 alpha Homo sapiens 59-63 15480072-2 2004 Under conditions of stress because of biomechanical factors, however, chondrocytes are capable of producing mediators that are associated with inflammation, including cytokines such as interleukin-1 and tumor necrosis factor-alpha, which in turn stimulate the production of prostaglandins and nitric oxide. Nitric Oxide 293-305 interleukin 1 alpha Homo sapiens 185-230 15223066-2 2004 A beta(25-35) upregulated the cytokine (TNF-alpha/IL-1 beta)-induced expression of iNOS and the production of nitric oxide (NO) in astrocytes, which were inhibited by vitamin E. Nitric Oxide 110-122 interleukin 1 alpha Homo sapiens 50-59 11953890-3 2002 Treatment of HT-29 cells with the nitric oxide donor Deta NONOate (50 nM) as well as induction of nitric oxide synthase II mRNA and production of endogenous nitric oxide by inflammatory cytokines (IFN-gamma and IL-1alpha) increased the invasiveness of HT-29 cells by approximately 40% and 75%, respectively. Nitric Oxide 34-46 interleukin 1 alpha Homo sapiens 211-220 12635941-2 2003 OBJECTIVE: To investigate the endogenous regulation of interleukin-1 (IL-1) cytokine network in osteoarthritic (OA) and rheumatoid (RA) cartilage in relation to nitric oxide (NO) production. Nitric Oxide 161-173 interleukin 1 alpha Homo sapiens 55-68 12635941-2 2003 OBJECTIVE: To investigate the endogenous regulation of interleukin-1 (IL-1) cytokine network in osteoarthritic (OA) and rheumatoid (RA) cartilage in relation to nitric oxide (NO) production. Nitric Oxide 161-173 interleukin 1 alpha Homo sapiens 70-74 14989423-3 2002 This accounts for the large amount of prostaglandin-E2 (PGE2), platelet activating factor and nitric oxide (NO) produced by cells exposed to IL-1 or in animals or humans injected with IL-1. Nitric Oxide 94-106 interleukin 1 alpha Homo sapiens 141-145 14989423-3 2002 This accounts for the large amount of prostaglandin-E2 (PGE2), platelet activating factor and nitric oxide (NO) produced by cells exposed to IL-1 or in animals or humans injected with IL-1. Nitric Oxide 94-106 interleukin 1 alpha Homo sapiens 184-188 12427115-4 2002 Ambroxol significantly attenuated the production of superoxide, hydrogen peroxide, HOCl, and nitric oxide in fMLP- or IL-1-activated phagocytic cells, while the inhibitory effects of antiinflammatory and thiol compounds were only observed in HOCl production. Nitric Oxide 93-105 interleukin 1 alpha Homo sapiens 118-122 11846032-6 2002 In response to interleukin-1, chondrocytes upregulate the production of nitric oxide and prostaglandin E2, two factors that have been shown to induce a number of the cellular changes associated with OA. Nitric Oxide 72-84 interleukin 1 alpha Homo sapiens 15-28 11927397-0 2002 Nitric oxide is involved in interleukin-1alpha-induced cytotoxicity in polarised human thyrocytes. Nitric Oxide 0-12 interleukin 1 alpha Homo sapiens 28-46 11592370-0 2001 Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Nitric Oxide 91-103 interleukin 1 alpha Homo sapiens 0-42 11263772-4 2001 The effect of recombinant OPN (or anti-OPN antiserum) on chondrocyte function was examined by analyzing the spontaneous or interleukin-1 (IL-1)-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2) from human OA-affected cartilage under ex vivo conditions. Nitric Oxide 163-175 interleukin 1 alpha Homo sapiens 123-142 11519352-0 2001 [Nitric oxide as main effector in the interleukin-1 system in ovulation]. Nitric Oxide 1-13 interleukin 1 alpha Homo sapiens 38-51 11519352-5 2001 The principal effector of the IL-1 system is nitric oxide. Nitric Oxide 45-57 interleukin 1 alpha Homo sapiens 30-34 11108714-5 2001 Interleukin-1 (IL-1) appears to mediate dsRNA + IFN-gamma-induced islet damage in a nitric oxide-dependent manner, as the interleukin-1 receptor antagonist protein prevents dsRNA + IFN-gamma-induced iNOS expression, inhibition of insulin secretion, and islet degeneration. Nitric Oxide 84-96 interleukin 1 alpha Homo sapiens 0-13 11108714-5 2001 Interleukin-1 (IL-1) appears to mediate dsRNA + IFN-gamma-induced islet damage in a nitric oxide-dependent manner, as the interleukin-1 receptor antagonist protein prevents dsRNA + IFN-gamma-induced iNOS expression, inhibition of insulin secretion, and islet degeneration. Nitric Oxide 84-96 interleukin 1 alpha Homo sapiens 15-19 11263774-1 2001 OBJECTIVE: To determine the effects of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists on interleukin-1 (IL-1) induction of nitric oxide (NO) and matrix metalloproteinase 13 (MMP-13) in human chondrocytes. Nitric Oxide 146-158 interleukin 1 alpha Homo sapiens 112-131 11069728-4 2000 However, there was a potent, dose-dependent inhibition of nitric oxide (NO) release from IL-1 alpha-stimulated BAC with an IC(50)of approximately 0.6 microM, with similar effects observed in primary chondrocytes. Nitric Oxide 58-70 interleukin 1 alpha Homo sapiens 89-99 11228400-1 2001 Interleukin-1 (IL-1) causes cartilage degradation through nitric oxide (NO) synthesis. Nitric Oxide 58-70 interleukin 1 alpha Homo sapiens 0-13 11228400-1 2001 Interleukin-1 (IL-1) causes cartilage degradation through nitric oxide (NO) synthesis. Nitric Oxide 58-70 interleukin 1 alpha Homo sapiens 15-19 11039768-6 2000 Human interleukin-1beta (5-10 ng/mL) induced nitric oxide, prostaglandin E2 and matrix metalloprotease production in bovine or human chondrocytes, which could be inhibited by 500 pg/mL of Type II interleukin-1 receptor. Nitric Oxide 45-57 interleukin 1 alpha Homo sapiens 6-19 11039768-8 2000 Similarly, 1 ng/mL human interleukin-1 induced (or spontaneously produced) nitric oxide and prostaglandin E2 production in human osteoarthritis-affected cartilage could be inhibited by 50% or greater with 100 pg/mL Type II interleukin-1 receptor in ex vivo conditions. Nitric Oxide 75-87 interleukin 1 alpha Homo sapiens 25-38 11110032-1 2000 Interleukin-1 (IL-1) is known to trigger induction of inducible nitric oxide synthase (iNOS) to persistently mass produce nitric oxide (NO) to induce various diseases such as cancer, inflammation, Alzheimer"s disease and eye diseases, including uveitis, retinopathy, age-related macular degeneration, glaucoma and myopia. Nitric Oxide 64-76 interleukin 1 alpha Homo sapiens 0-13 11110032-1 2000 Interleukin-1 (IL-1) is known to trigger induction of inducible nitric oxide synthase (iNOS) to persistently mass produce nitric oxide (NO) to induce various diseases such as cancer, inflammation, Alzheimer"s disease and eye diseases, including uveitis, retinopathy, age-related macular degeneration, glaucoma and myopia. Nitric Oxide 64-76 interleukin 1 alpha Homo sapiens 15-19 10052722-0 1998 Nitric oxide suppresses bFGF- and IL-1-alpha-mediated but not VEGF165-mediated angiogenesis in natively vascularized mammalian tissue. Nitric Oxide 0-12 interleukin 1 alpha Homo sapiens 34-44 10329302-3 1999 Interleukin-1 (IL-1) plays an important role in the pathogenesis of osteoarthritis (OA) either directly or through the stimulation of catabolic factors, such as nitric oxide (NO). Nitric Oxide 161-173 interleukin 1 alpha Homo sapiens 0-13 10329302-3 1999 Interleukin-1 (IL-1) plays an important role in the pathogenesis of osteoarthritis (OA) either directly or through the stimulation of catabolic factors, such as nitric oxide (NO). Nitric Oxide 161-173 interleukin 1 alpha Homo sapiens 15-19 9880560-1 1999 Osteoblasts respond to stimulation with interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) by production of nitric oxide and prostaglandins (PGs). Nitric Oxide 153-165 interleukin 1 alpha Homo sapiens 55-59 10912912-5 2000 We further show that pretreatment of human internal thoracic artery and cardiac atrial endothelium with the proinflammatory cytokines interleukin-1-alpha and -beta led to a significant increase in both the expression of the mu transcript and in morphine-stimulated nitric oxide release measured amperometrically. Nitric Oxide 265-277 interleukin 1 alpha Homo sapiens 134-163 10358077-2 1999 A combination of the pro-inflammatory cytokines interleukin (IL)-1alpha, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha induces nitric oxide synthase mRNA expression and nitric oxide (NO) generation in the human colon carcinoma cell line HT-29. Nitric Oxide 143-155 interleukin 1 alpha Homo sapiens 48-71 9914865-6 1999 Studies in human vessels suggest that interleukin-1 is particularly important as a mediator of inflammatory dilatation; the underlying mechanisms include induction of the inducible isoform of nitric oxide synthase in vascular smooth muscle, or over-production of nitric oxide from the endothelial isoform of nitric oxide synthase. Nitric Oxide 192-204 interleukin 1 alpha Homo sapiens 38-51 10052722-7 1998 These data suggest that nitric oxide can act as an endogenous suppressor of mammalian de novo angiogenesis, which is a new finding, and, moreover, that angiogenesis induced by VEGF165 on the one hand and by bFGF and IL-1 on the other in the rat mesenteric window depends on different pathways. Nitric Oxide 24-36 interleukin 1 alpha Homo sapiens 216-220 9691088-6 1998 These results indicate that the inhibitory effects of TNF + LPS + IFN-gamma are mediated by nitric oxide, produced by the actions of IL-1 released endogenously within human islets. Nitric Oxide 92-104 interleukin 1 alpha Homo sapiens 133-137 9795242-1 1998 Incubation of human articular cartilage explants with interleukin-1alpha (IL-1alpha) inhibited the rate of [35S]sulphate incorporation into glycosaminoglycan (GAG) chains concomitant with an increase in nitric oxide (NO) production. Nitric Oxide 203-215 interleukin 1 alpha Homo sapiens 54-72 9795242-1 1998 Incubation of human articular cartilage explants with interleukin-1alpha (IL-1alpha) inhibited the rate of [35S]sulphate incorporation into glycosaminoglycan (GAG) chains concomitant with an increase in nitric oxide (NO) production. Nitric Oxide 203-215 interleukin 1 alpha Homo sapiens 74-83 9765278-0 1998 Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes. Nitric Oxide 85-97 interleukin 1 alpha Homo sapiens 63-76 9765278-2 1998 The GC inhibitors LY83583 and methylene blue dose-dependently inhibited IL-1-induced nitric oxide (NO) production, inducible NO synthase (iNOS) protein, and mRNA expression. Nitric Oxide 85-97 interleukin 1 alpha Homo sapiens 72-76 9719467-8 1998 Furthermore, the cytokines IL-1, TNFalpha, and IFNgamma are cytotoxic to beta-cells, in large part by inducing the formation of oxygen free radicals, nitric oxide, and peroxynitrite in the beta-cells themselves. Nitric Oxide 150-162 interleukin 1 alpha Homo sapiens 27-31 20654397-5 1998 Stimulation of interleukin-1alpha release from the A431 human keratinocyte cell line reflected in vivo erythema scores more closely than cytotoxic potential, and coincided with nitric oxide production by macrophages upon exposure to A431-conditioned medium. Nitric Oxide 177-189 interleukin 1 alpha Homo sapiens 15-33 9565081-1 1998 Slices of lapine meniscus produced large amounts of nitric oxide after stimulation with interleukin-1, tumor necrosis factor alpha, or a mixture of lapine synovial cytokines known as chondrocyte-activating factors. Nitric Oxide 52-64 interleukin 1 alpha Homo sapiens 88-130 9570565-1 1998 During inflammatory joint diseases, chondrocytes are exposed to cytokines such as IL-1 that induce the synthesis of nitric oxide (NO). Nitric Oxide 116-128 interleukin 1 alpha Homo sapiens 82-86 9565081-7 1998 Endogenously generated nitric oxide suppressed the synthesis of collagen and proteoglycan by menisci but protected proteoglycan from the catabolic effects of interleukin-1. Nitric Oxide 23-35 interleukin 1 alpha Homo sapiens 158-171 9254084-14 1997 It is therefore likely that fever, leukocytosis, and nitric oxide synthesis are also mediated by IL-1 in patients suffering from SAH and it is probable that the inflammatory mediators contribute to brain damage. Nitric Oxide 53-65 interleukin 1 alpha Homo sapiens 97-101 9299442-2 1997 To clarify the functional role of amniotic IL-1 alpha, we studied its effect on the induction of nitric oxide (NO) synthesis in the uterus. Nitric Oxide 97-109 interleukin 1 alpha Homo sapiens 43-53 9151802-6 1997 The ability of IL-1 to upregulate Glut1 and Glut3 transcripts proved time-, dose-, nitric oxide-, and protein biosynthesis-dependent but glucose independent. Nitric Oxide 83-95 interleukin 1 alpha Homo sapiens 15-19 8557627-0 1996 Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. Nitric Oxide 139-151 interleukin 1 alpha Homo sapiens 0-13 8557627-2 1996 IL-1 increases islet expression of nitric oxide (NO) synthase, and the resultant overproduction of NO participates in inhibition of insulin secretion because NO synthase inhibitors, e.g. NG-monomethyl-arginine (NMMA), prevent this inhibition. Nitric Oxide 35-47 interleukin 1 alpha Homo sapiens 0-4 8903851-4 1995 The results have shown that interleukin-1 (IL-1) is a potent activator of human astrocytes and induces cytokines such as tumor necrosis factor alpha and interleukin-6, and is a potent activator of nitric oxide generation in astrocytes. Nitric Oxide 197-209 interleukin 1 alpha Homo sapiens 28-41 8546706-0 1996 A redox-based mechanism for induction of interleukin-1 production by nitric oxide in a human colonic epithelial cell line (HT29-Cl.16E). Nitric Oxide 69-81 interleukin 1 alpha Homo sapiens 41-54 8903851-4 1995 The results have shown that interleukin-1 (IL-1) is a potent activator of human astrocytes and induces cytokines such as tumor necrosis factor alpha and interleukin-6, and is a potent activator of nitric oxide generation in astrocytes. Nitric Oxide 197-209 interleukin 1 alpha Homo sapiens 43-47 8903852-0 1995 Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Nitric Oxide 100-112 interleukin 1 alpha Homo sapiens 0-45 7721426-1 1995 Prolonged incubation with 1 nmol/L interleukin-1 induced high levels of nitric oxide release and cytotoxicity in vascular smooth muscle cells. Nitric Oxide 72-84 interleukin 1 alpha Homo sapiens 35-48 7578979-5 1995 In previous studies, IL-1 increased immunoreactive cGMP production in human saphenous VSMC through a pathway inhibitable by soluble guanylate cyclase inhibitors, methylene blue and LY83583, but not by nitric oxide (NO) synthase inhibitors, suggesting a role of NO-independent activation of soluble guanylate cyclase. Nitric Oxide 201-213 interleukin 1 alpha Homo sapiens 21-25 7721426-6 1995 Coculture study of vascular smooth muscle cells and endothelial cells without direct cell contact revealed that incubation for 72 hours with interleukin-1 induced high levels of nitric oxide release from cocultured vascular smooth muscle cells to the same degree as release from vascular smooth muscle cells alone. Nitric Oxide 178-190 interleukin 1 alpha Homo sapiens 141-154 7721426-2 1995 NG-Monomethyl-L-arginine, an inhibitor of nitric oxide synthesis, inhibited interleukin-1-induced cytotoxicity at a concentration of 3 mmol/L. Nitric Oxide 42-54 interleukin 1 alpha Homo sapiens 76-89 7926002-5 1994 These data suggest that interleukin-1 suppresses synthesis of the cartilaginous matrix through more than one mechanism, at least one of which is dependent upon the production of nitric oxide. Nitric Oxide 178-190 interleukin 1 alpha Homo sapiens 24-37 7926002-1 1994 Interleukin-1 alpha and beta induced the production of large amounts of nitric oxide by normal, human articular chondrocytes in alginate culture; at the same time the biosynthesis of proteoglycan was strongly suppressed. Nitric Oxide 72-84 interleukin 1 alpha Homo sapiens 0-19 1541678-1 1992 An interferon-gamma, tumor necrosis factor, and interleukin-1-inducible, high-output pathway synthesizing nitric oxide (NO) from L-arginine was recently identified in rodents. Nitric Oxide 106-118 interleukin 1 alpha Homo sapiens 48-61 7534178-1 1994 In vascular smooth muscle cells (VSMC), inflammatory cytokines such as interleukin 1 (IL1) and tumour necrosis factor alpha (TNF alpha) stimulate nitric oxide (NO) production via the expression of an inducible type of NO synthase (iNOS). Nitric Oxide 146-158 interleukin 1 alpha Homo sapiens 71-84 7534178-1 1994 In vascular smooth muscle cells (VSMC), inflammatory cytokines such as interleukin 1 (IL1) and tumour necrosis factor alpha (TNF alpha) stimulate nitric oxide (NO) production via the expression of an inducible type of NO synthase (iNOS). Nitric Oxide 146-158 interleukin 1 alpha Homo sapiens 86-89 7505803-0 1994 Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. Nitric Oxide 104-116 interleukin 1 alpha Homo sapiens 0-13 1456666-4 1992 This study also confirmed the protective effects of IL-1 in experimental NSAID-gastropathy, and demonstrates that one of the ways the IL-1 may protect the mucosa is through its ability to inhibit the release of proinflammatory mediators (e.g., PAF) and promote the release of antiinflammatory mediators (e.g., nitric oxide). Nitric Oxide 310-322 interleukin 1 alpha Homo sapiens 134-138 1658153-2 1991 The present study shows that IL-1 induces the biosynthesis of nitric oxide (.N = O) by articular chondrocytes. Nitric Oxide 62-74 interleukin 1 alpha Homo sapiens 29-33 33804447-0 2021 Inhibition of Inducible Nitric Oxide Synthase Prevents IL-1beta-Induced Mitochondrial Dysfunction in Human Chondrocytes. Nitric Oxide 24-36 interleukin 1 alpha Homo sapiens 55-63 33804447-1 2021 Interleukin (IL)-1beta is an important pro-inflammatory cytokine in the progression of osteoarthritis (OA), which impairs mitochondrial function and induces the production of nitric oxide (NO) in chondrocytes. Nitric Oxide 175-187 interleukin 1 alpha Homo sapiens 0-22 35094658-7 2022 IL-1beta-induced high secretion levels of nitric oxide and prostaglandin 2, TNF-alpha, IL-6 and MCP-1 were down-regulated by TB-II treatment, indicating an anti-inflammatory effect of TB-II on OA in vitro condition. Nitric Oxide 42-54 interleukin 1 alpha Homo sapiens 0-8 34072123-5 2021 In the current study, we determined that treating interleukin-1 beta (IL-1beta-stimulated chondrocyte cells) with cardamonin significantly reduced the release of nitric oxide (NO) and prostaglandin E2 (PGE2) and significantly inhibited the expression of pro-inflammatory proteins, including inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2). Nitric Oxide 162-174 interleukin 1 alpha Homo sapiens 70-78 34908254-8 2021 Hyperglycemia also increases serum Nitric Oxide (NO), which decreases neutrophil motility and reduces the synthesis and release of various inflammatory mediators such as TNF-alpha and IL-1beta, IL-6. Nitric Oxide 35-47 interleukin 1 alpha Homo sapiens 184-192 34739636-4 2022 Our results showed that the IL-1beta-stimulated production of inflammatory mediators including nitric oxide (NO), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 were suppressed by GAA. Nitric Oxide 95-107 interleukin 1 alpha Homo sapiens 28-36 35578178-3 2022 METHODS: We recruited 132 subjects, detected IL1-RL1 protein level in sputum supernatant by ELISA, and analyzed the correlation between the expression level of IL1-RL1 and fraction of exhaled nitric oxide (FeNO), IgE, peripheral blood eosinophil count (EOS#), and Th2 cytokines (IL-4, IL-5, IL-10, IL-13, IL-33 and TSLP) and Th1 cytokines (IFN-gamma, IL-2, IL-8). Nitric Oxide 192-204 interleukin 1 alpha Homo sapiens 160-163 33100269-2 2020 In response to encephalomyocarditis virus (EMCV) infection, resident islet macrophages release the pro-inflammatory cytokine IL-1beta, to levels that are sufficient to stimulate inducible nitric oxide synthase (iNOS) expression and production of micromolar levels of the free radical nitric oxide in neighboring beta-cells. Nitric Oxide 188-200 interleukin 1 alpha Homo sapiens 125-133 33680110-8 2021 The results demonstrated that OrA significantly attenuated the upregulation of inducible nitric oxide synthase and cyclooxygenase 2 by IL-1beta at both protein and mRNA levels. Nitric Oxide 89-101 interleukin 1 alpha Homo sapiens 135-143 33100269-2 2020 In response to encephalomyocarditis virus (EMCV) infection, resident islet macrophages release the pro-inflammatory cytokine IL-1beta, to levels that are sufficient to stimulate inducible nitric oxide synthase (iNOS) expression and production of micromolar levels of the free radical nitric oxide in neighboring beta-cells. Nitric Oxide 284-296 interleukin 1 alpha Homo sapiens 125-133 33016027-11 2020 Furthermore, in these immune cells, IL-1 also elevates nitric oxide, and the release of inflammatory arachidonic acid products such as prostaglndins and thromboxane A2. Nitric Oxide 55-67 interleukin 1 alpha Homo sapiens 36-40 32972972-3 2020 Furthermore, IL-1 is known to stimulate beta-cell expression of iNOS and production of the free radical nitric oxide. Nitric Oxide 104-116 interleukin 1 alpha Homo sapiens 13-17 32058211-4 2020 in vitro study, IL-1beta-induced expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), Nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), prostaglandin E2 (PGE2), and interleukin-6 (IL-6) were inhibited by Ellagic acid (EA). Nitric Oxide 113-125 interleukin 1 alpha Homo sapiens 16-24 32450530-3 2020 Here, we investigated the effects of Imperatorin on interleukin-1beta (IL-1beta) induced expression of inducible nitric oxide synthase (iNOS) and nitric oxide production in primary human OA chondrocytes and cartilage explants culture under pathological conditions and explored the associated signaling pathways. Nitric Oxide 113-125 interleukin 1 alpha Homo sapiens 71-79 32252155-8 2020 COX-2 inhibition initially enhanced and subsequently reduced IL-1beta induced inducible nitric oxide synthase, without altering medium nitrite. Nitric Oxide 88-100 interleukin 1 alpha Homo sapiens 61-69 32757662-6 2020 Knockdown of TRIM8 attenuated IL-1beta-induced production of inflammatory mediators including nitric oxide and prostaglandin E2. Nitric Oxide 94-106 interleukin 1 alpha Homo sapiens 30-38 32757662-7 2020 The increased expression levels of inducible nitric oxide synthase and cyclooxygenase-2 in IL-1beta-induced chondrocytes were suppressed by TRIM8 knockdown. Nitric Oxide 45-57 interleukin 1 alpha Homo sapiens 91-99